Pappas-PT · Source catalogue

Patent for a therapeutic device that strikes a pulsed arc discharge (plasma) between hemispherical electrodes in a chamber fed with air or selected gases (nitrogen, argon). The arc is driven by rectified, stored-capacitor square-wave energy from a variable transformer and timer. The cathode is wired to a 30 cm induction coil (2-10 turns, in an insulated toroid) on a flexible tail that is placed over the patient. The patent states that the oscilloscope shows a slow damped LCR sinusoid with short bursts (stated as under 1 microsecond in the description, 1e-4 to 1e-6 s in claim 14 and under 1e-4 s in claim 16; about 10-15 per train, the first unequal, duty cycle about 0.001%) of radio-frequency 'eigenoscillations' of the gas plasma at each sinusoid extremum. Figures 2-3 show oscillograms with frequency readouts (e.g. 110.033 MHz labelled 'average', max 240.309 MHz; the readout is identical on FIGS. 2 and 3, has no vertical scale and is not a spectrum). The stated rationale: healthy cells have about 70 mV transmembrane potential, aged or unhealthy cells about 50 mV, cancer cells about 15 mV; restoring potential needs fields the patent prints as 10^6 V/m (page image p.4), which it says exceeds the dielectric strength of air if applied as a steady or sinusoidal field. The invention claims to avoid air ionization by delivering voltage 1-100 times the dielectric value of air for intervals shorter than molecular-vibration timescales. The patent also says the burst frequencies resonate with elements in cells, selectively exciting e.g. nitrogen, and initiating selected endothermic chemical reactions, and that the effect can 'pasteurize' degenerate cells or microorganisms by pressure increase. Pappas reports measuring instantaneous voltage and current 10-100 times larger than available potential and average current in an oscillating arc. He explains this by arc resistance going from infinite before ignition to under 0.5 ohm and then to about -100 ohm, giving theoretical 'infinite gain' then negative gain (cited with Langmuir 1925 plasma oscillations). The patent also notes prior art by Nordenstrom (invasive electrodes for cancer) and cites US 4,369,345 (Czerlinski). 17 claims: claims 1-16 apparatus (plasma means, radio eigenfrequency excitation, induction probe, coil specs, capacitor storage, electrode geometry, burst duration, duty cycle); claim 17 a method. No clinical or biological data are given in the digested text; the evidence presented is oscillograms of the electrical output. ADDITIONS FROM QE AND THE DEEP READ. (1) The patent prints 10^6 V/m for BOTH the membrane field (70 mV over 'several Angstrom') and the dielectric strength of air ('10 Kv/cm, or just 10^6 v/m') [read: page image p.4]; this is internally inconsistent: the membrane value for 70 mV is about 1.4e7 V/m (5 nm) to 2.3e8 V/m (3 Angstrom) and air is about 3e6 V/m [calc, by the arbiter and QE]. (2) Coil current: the induction coil is designed 'to provide very high rates of power, current >1000amps' and claim 5 says 'at least 1000 amps' [read: p.6-7]; this is the only electrical current the patent states. (3) The patent states 'Cells with a low transmembrane potential are the source of pain generation signals' [read: p.4], a distinct claim bearing on later pain trials. (4) Unquantified efficacy and penetration statements [read: p.5]: 'found to be effective to the same degree as microcontact'; 'may even be applied over ordinary clothing'; penetration depth 'proportional to the intensity of the applied field ... can reach any desired depth' (a later clinical paper repeats the manufacturer's 'about 20 cm' [web: https://pmc.ncbi.nlm.nih.gov/articles/PMC12534222/]). (5) Prior art cited in full [read: p.1]: Czerlinski US 4,369,345; Gordon US 4,622,953; Liboff et al. US 5,160,591 (ion cyclotron resonance, regulating transmembrane ion movement with selective harmonic frequencies); the text also names Nordenstrom's invasive electrode cancer method as 'quite successful' [read: p.4]. (6) Digest error corrected by the deep read: 110.033 MHz is the scope's 'average', not a 'reference frequency' [read: p.3].

Key claims

• An arc-discharge plasma in air or selected gases produces transient voltage and current 10-100 times greater than the supplied potential and average current.
• Arc plasma resistance falls from infinite to under 0.5 ohm on ignition and then to about -100 ohm, giving 'infinite' then negative gain and excess power for short intervals.
• The discharge delivers bursts at plasma 'eigenfrequencies' (radio range, tens to hundreds of MHz in the figures) through an induction coil without ionizing the surrounding air; burst length is stated as under 1e-6 s (description), 1e-4 to 1e-6 s (claim 14) and under 1e-4 s (claim 16).
• Pulses can briefly exceed the dielectric strength of air by 1-100 times because they end before breakdown occurs; the patent prints 10^6 V/m both as the field needed at the membrane and as air's strength.
• Cell elements resonate with the plasma eigenfrequencies and selectively absorb the burst energy, which initiates selected endothermic chemical reactions with therapeutic effect (no frequency is given for any element).
• A nitrogen-containing plasma can selectively excite nitrogen in biological matter.
• Restoring cell transmembrane potential (cancer about 15 mV, unhealthy about 50 mV, healthy about 70 mV) by induced fields has therapeutic effect, including against cancer.
• Cells with a low transmembrane potential are the source of pain generation signals.
• The pulses can 'pasteurize' degenerate cells or microorganisms by increased pressure.
• The induction coil carries a current of at least 1000 A (claim 5; description 'current >1000amps').

Relevance: It is the only document in the project and carries all of the central claims: negative-resistance arc as an energy gain mechanism, nanosecond-microsecond burst therapy by magnetic induction, and resonance-selective biochemical effects.

Mainstream conflict: Likely conflicts (to be judged by the reviewers, not decided here): 'infinite gain' from arc resistance is not an energy source, since the stored capacitor energy and a negative differential resistance do not create net power; the 'excess' voltage and current may come from stored energy in L and C; resonant absorption selecting chemical reactions in tissue at tens to hundreds of MHz is not an accepted mechanism; therapeutic efficacy (cancer, restoring transmembrane potential) is not supported by data in the patent. Patent grant is not clinical validation. The prior art the patent cites includes Liboff et al. (ion cyclotron resonance), a mainstream-adjacent resonance idea that needs a static magnetic field; the patent's own 10^6 V/m figure for air strength is about a factor of 3 too low, and its membrane-field figure is 14-230 times too low.